BioAlliance Pharma has announced preliminary results from its Doxorubicin transdrug Phase I/II clinical trial for primary liver cancer.

Doxorubicin transdrug has been granted orphan drug status by the EMEA and the FDA for the treatment of hepatocellular carcinoma, the most lethal form of liver cancer, and for which no approved treatment exists.

Transdrug is a treatment based on nanotechnology developed by BioAlliance Pharma. It allows intracellular drug-targeting to optimize drug efficacy and patient tolerance.